Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age.
Co-administration of oral live-attenuated human rotavirus vaccine RIX4414 (Rotarix) and oral polio vaccine (OPV) was assessed. Healthy infants were randomised to receive 2-doses of either: RIX4414 or placebo co-administered with OPV (12 and 16 weeks of age); or RIX4414 or placebo given 15 days after OPV. After vaccination, 56.5-66.7% of RIX4414 and 18.6% of placebo recipients had seroconverted for rotavirus IgA. No significant differences between RIX4414 groups with or without OPV co-administration were observed. No statistically significant differences were observed between groups for polio seroprotection rates. RIX4414 vaccine was immunogenic when co-administered with OPV and did not interfere with OPV seroprotection rates.
Zaman
K
K
International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B), GPO Box-128, Mohakhali, Dhaka 1000, Bangladesh.
Sack
D A
DA
Yunus
M
M
Arifeen
S E
SE
Podder
G
G
Azim
T
T
Luby
S
S
Breiman
R F
RF
Neuzil
K
K
Datta
S K
SK
Delem
A
A
Suryakiran
P V
PV
Bock
H L
HL
D000284:Administration, Oral; D000914:Antibodies, Viral / Q000097:blood; D000917:Antibody Formation; D001459:Bangladesh / Q000453:epidemiology; D003967:Diarrhea / Q000453:epidemiology / Q000276:immunology / Q000821:virology; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005759:Gastroenteritis / Q000453:epidemiology / Q000209:etiology / Q000276:immunology; D006801:Humans; D007223:Infant; D008297:Male; D011051:Poliomyelitis / Q000276:immunology; D023321:Poliovirus Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*; D012400:Rotavirus Infections / Q000453:epidemiology / Q000276:immunology*; D022243:Rotavirus Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*
D000914:Antibodies, Viral; D023321:Poliovirus Vaccines; D022243:Rotavirus Vaccines